Immunomodulatory Yersinia outer proteins (Yops)–useful tools for bacteria and humans alike

References

• Akopyan K, Edgren T, Wang-Edgren H, Rosqvist R, Fahlgren A, Wolf-Watz H, Fallman M. Translocation of surface-localized effectors in type III secretion. Proc Natl Acad Sci U S A 2011; 108(4):1639-44; PMID:21220342; http://dx.doi.org/10.1073/pnas.1013888108
   PubMed Web of Science ®Google Scholar
• Dean P. Functional domains and motifs of bacterial type III effector proteins and their roles in infection. FEMS Microbiol Rev 2011; 35(6):1100-25; PMID:21517912; http://dx.doi.org/10.1111/j.1574-6976.2011.00271.x
   PubMed Web of Science ®Google Scholar
• Portaliou AG, Tsolis KC, Loos MS, Zorzini V, Economou A. Type III secretion: Building and operating a remarkable nanomachine. Trends Biochem Sci 2016; 41(2):175-89; PMID:26520801; http://dx.doi.org/10.1016/j.tibs.2015.09.005
   PubMed Web of Science ®Google Scholar
• Santos AS, Finlay BB. Bringing down the host: Enteropathogenic and enterohaemorrhagic Escherichia coli effector-mediated subversion of host innate immune pathways. Cell Microbiol 2015; 17(3):318-32; PMID:25588886; http://dx.doi.org/10.1111/cmi.12412
   PubMed Web of Science ®Google Scholar
• Rüter C, Hardwidge PR. “Drugs from Bugs:” Bacterial effector proteins as promising biological (immune-) therapeutics. FEMS Microbiol Lett 2013; 351(2):126-32; PMID:24261744; http://dx.doi.org/10.1111/1574-6968.12333
   PubMed Web of Science ®Google Scholar
• Rüter C, Schmidt MA. Cell-penetrating bacterial effector proteins: Better tools than targets. Trends Biotechnol 2017; 35(2):109-20; PMID:27592802; http://dx.doi.org/10.1016/j.tibtech.2016.08.002
   PubMed Web of Science ®Google Scholar
• Michgehl S, Heusipp G, Greune L, Rüter C, Schmidt MA. Esp-independent functional integration of the translocated intimin receptor (Tir) of enteropathogenic Escherichia coli (EPEC) into host cell membranes. Cell Microbiol 2006; 8(4):625-33; PMID:16548888; http://dx.doi.org/10.1111/j.1462-5822.2005.00655.x
   PubMed Web of Science ®Google Scholar
• Cirl C, Wieser A, Yadav M, Duerr S, Schubert S, Fischer H, Stappert D, Wantia N, Rodriguez N, Wagner H, et al. Subversion of toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nat Med 2008; 14(4):399-406; PMID:18327267; http://dx.doi.org/10.1038/nm1734
   PubMed Web of Science ®Google Scholar
• Waldhuber A, Snyder G, Römmler F, Cirl C, Müller T, Xiao T, Svanborg C, Miethke T. A comparative analysis of the mechanism of toll-like receptor-disruption by TIR-containing protein C from uropathogenic Escherichia coli. Pathogens 2016; 5(1):25; PMID:26938564; http://dx.doi.org/10.3390/pathogens5010025
   PubMed Web of Science ®Google Scholar
• Stolle A. The recombinant EPEC effector NleC follows uptake strategies similar to short-trip AB toxins and displays immunosuppressive features by cleaving p65 [Dissertation]. Münster, Germany: Westfälische Wilhelms-Universität; 2016
   Google Scholar
• Lubos M, Norkowski S, Stolle A, Langel Ü, Schmidt MA, Rüter C. Analysis of T3SS-independent autonomous internalization of the bacterial effector protein SspH1 from Salmonella typhimurium. Inflamm Cell Signal 2014; (1):e423; http://dx.doi.org/10.14800/ics.423
   Google Scholar
• Lubos M, Schmidt MA, Rüter C, inventors; Westfälische Wilhelms-Universität Münster, assignee. Cell-penetrating bacterial E3-ubiquitin-ligases for use in immunotherapy. WO/2015/040215. 2015 Mar 26
   Google Scholar
• Rüter C, Buss C, Scharnert J, Heusipp G, Schmidt MA. A newly identified bacterial cell-penetrating peptide that reduces the transcription of pro-inflammatory cytokines. J Cell Sci 2010; 123(13):2190-8; PMID:20554895; http://dx.doi.org/10.1242/jcs.063016
   PubMed Web of Science ®Google Scholar
• Scharnert J, Greune L, Zeuschner D, Lubos M, Schmidt MA, Rüter C. Autonomous translocation and intracellular trafficking of the cell-penetrating and immune-suppressive effector protein YopM. Cell Mol Life Sci 2013; 70(24):4809-23; PMID:23835836; http://dx.doi.org/10.1007/s00018-013-1413-2
   PubMed Web of Science ®Google Scholar
• Rohde JR, Breitkreutz A, Chenal A, Sansonetti PJ, Parsot C. Type III secretion effectors of the IpaH family are E3 ubiquitin ligases. Cell Host Microbe 2007; 1(1):77-83; PMID:18005683; http://dx.doi.org/10.1016/j.chom.2007.02.002
   PubMed Web of Science ®Google Scholar
• Dinca A, Chien W, Chin MT. Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease. Int J Mol Sci 2016; 17(2):263; PMID:26907261; http://dx.doi.org/10.3390/ijms17020263
   PubMed Web of Science ®Google Scholar
• Kurrikof K, Gestin M, Langel Ü. Recent in vivo advances in cell-penetrating peptide-assisted drug delivery. Expert Opin Drug Deliv 2016; 13(3):373-87; PMID: 26634750; http://dx.doi.org/10.1517/17425247.2016.1125879
   Web of Science ®Google Scholar
• Cornelis GR, Biot T, Lambert de Rouvroit C, Michiels T, Mulder B, Sluiters C, Sory MP, van Bouchaute M, Vanooteghem JC. The Yersinia yop regulon. Mol Microbiol 1989; 3(10):1455-9; PMID:2693899; http://dx.doi.org/10.1111/j.1365-2958.1989.tb00129.x
   PubMed Web of Science ®Google Scholar
• Cornelis GR, Wolf-Watz H. The Yersinia Yop virulon: A bacterial system for subverting eukaryotic cells. Mol Microbiol 1997; 23(5):861-7; PMID:9076724; http://dx.doi.org/10.1046/j.1365-2958.1997.2731623.x
   PubMed Web of Science ®Google Scholar
• Bliska JB. Yop effectors of Yersinia spp. and actin rearrangements. Trends Microbiol 2000; 8(5):205-8; PMID:10785635; http://dx.doi.org/10.1016/S0966-842X(00)01738-8
   PubMed Web of Science ®Google Scholar
• Cornelis GR. The Yersinia Ysc-Yop ‘type III’ weaponry. Nat Rev Mol Cell Biol 2002; 3(10):742-52; PMID:12360191; http://dx.doi.org/10.1038/nrm932
   PubMed Web of Science ®Google Scholar
• Viboud GI, Bliska JB. Yersinia outer proteins: Role in modulation of host cell signaling responses and pathogenesis. Annu Rev Microbiol 2005; 59:69-89; PMID:15847602; http://dx.doi.org/10.1146/annurev.micro.59.030804.121320
   PubMed Web of Science ®Google Scholar
• Ruckdeschel K, Deuretzbacher A, Haase R. Crosstalk of signalling processes of innate immunity with Yersinia Yop effector functions. Immunobiology 2008; 213(3–4):261-9; PMID:18406372; http://dx.doi.org/10.1016/j.imbio.2007.11.001
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Young GM. Translocated effectors of Yersinia. Curr Opin Microbiol 2009; 12(1):94-100; PMID:19185531; http://dx.doi.org/10.1016/j.mib.2008.12.005
   PubMed Web of Science ®Google Scholar
• Pha K, Navarro L. Yersinia type III effectors perturb host innate immune responses. World J Biol Chem 2016; 7(1):1-13; PMID:26981193; http://dx.doi.org/10.4331/wjbc.v7.i1.1
   PubMedGoogle Scholar
• Thorslund SE, Edgren T, Pettersson J, Nordfelth R, Sellin ME, Ivanova E, Francis MS, Isaksson EL, Wolf-Watz H, Fallman M. The RACK1 signaling scaffold protein selectively interacts with Yersinia pseudotuberculosis virulence function. PLoS One 2011; 6(2):e16784; PMID:21347310; http://dx.doi.org/10.1371/journal.pone.0016784
   PubMed Web of Science ®Google Scholar
• Dewoody R, Merritt PM, Marketon MM. YopK controls both rate and fidelity of Yop translocation. Mol Microbiol 2013; 87(2):301-17; PMID:23205707; http://dx.doi.org/10.1111/mmi.12099
   PubMed Web of Science ®Google Scholar
• Miao EA, Scherer CA, Tsolis RM, Kingsley RA, Adams LG, Baumler AJ, Miller SI. Salmonella typhimurium leucine-rich repeat proteins are targeted to the SPI1 and SPI2 type III secretion systems. Mol Microbiol 1999; 34(4):850-64; PMID:10564523; http://dx.doi.org/10.1046/j.1365-2958.1999.01651.x
   PubMed Web of Science ®Google Scholar
• Wei C, Wang Y, Du Z, Guan K, Cao Y, Yang H, Zhou P, Wu F, Chen J, Wang P, et al. The Yersinia type III secretion effector YopM is an E3 ubiquitin ligase that induced necrotic cell death by targeting NLRP3. Cell Death Dis 2016; 7(12):e2519; PMID:27929533; http://dx.doi.org/10.1038/cddis.2016.413
   PubMedGoogle Scholar
• Evdokimov AG, Anderson DE, Routzahn KM, Waugh DS. Unusual molecular architecture of the Yersinia pestis cytotoxin YopM: A leucine-rich repeat protein with the shortest repeating unit. J Mol Biol 2001; 312(4):807-21; PMID:11575934; http://dx.doi.org/10.1006/jmbi.2001.4973
   PubMed Web of Science ®Google Scholar
• Benabdillah R, Mota LJ, Lützelschwab S, Demoinet E, Cornelis GR. Identification of a nuclear targeting signal in YopM from Yersinia spp. Microb Pathog 2004; 36(5):247-61; PMID:15043860; http://dx.doi.org/10.1016/j.micpath.2003.12.006
   PubMed Web of Science ®Google Scholar
• Boland A, Sory MP, Iriarte M, Kerbourch C, Wattiau P, Cornelis GR. Status of YopM and YopN in the Yersinia Yop virulon: YopM of Y. enterocolitica is internalized inside the cytosol of PU5-1.8 macrophages by the YopB, D, N delivery apparatus. EMBO J 1996; 15(19):5191-5201; PMID:8895564
   PubMed Web of Science ®Google Scholar
• Höfling S, Scharnert J, Cromme C, Bertrand J, Pap T, Schmidt MA, Rüter C. Manipulation of pro-inflammatory cytokine production by the bacterial cell-penetrating effector protein YopM is independent of its interaction with host cell kinases RSK1 and PRK2. Virulence 2014; 5(7):761-71; PMID:25513777; http://dx.doi.org/10.4161/viru.29062
   PubMed Web of Science ®Google Scholar
• Höfling S, Grabowski B, Norkowski S, Schmidt MA, Rüter C. Current activities of the Yersinia effector protein YopM. Int J Med Microbiol 2015; 305(3):424-32; PMID:25865799; http://dx.doi.org/10.1016/j.ijmm.2015.03.009
   PubMed Web of Science ®Google Scholar
• Reisner BS, Straley SC. Yersinia pestis YopM: Thrombin binding and overexpression. Infect Immun 1992; 60(12):5242-52; PMID:1452357
   PubMed Web of Science ®Google Scholar
• Hines J, Skrzypek E, Kajava AV, Straley SC. Structure-function analysis of Yersinia pestis YopM's interaction with alpha-thrombin to rule on its significance in systemic plague and to model YopM's mechanism of binding host proteins. Microb Pathog 2001; 30(4):193-209; PMID:11312613; http://dx.doi.org/10.1006/mpat.2000.0424
   PubMed Web of Science ®Google Scholar
• Heusipp G, Spekker K, Brast S, Fälker S, Schmidt MA. YopM of Yersinia enterocolitica specifically interacts with alpha 1-antitrypsin without affecting the anti-protease activity. Microbiology 2006; 152(5):1327-35; PMID:16622050; http://dx.doi.org/10.1099/mic.0.28697-0
   PubMed Web of Science ®Google Scholar
• Cheng LW, Schneewind O. Yersinia enterocolitica TyeA, an intracellular regulator of the type III machinery, is required for specific targeting of YopE, YopH, YopM, and YopN into the cytosol of eukaryotic cells. J Bacteriol 2000; 182(11):3183-90; PMID:10809698; http://dx.doi.org/10.1128/JB.182.11.3183-3190.2000
   PubMed Web of Science ®Google Scholar
• McDonald C, Vacratsis PO, Bliska JB, Dixon JE. The yersinia virulence factor YopM forms a novel protein complex with two cellular kinases. J Biol Chem 2003; 278(20):18514-23; PMID:12626518; http://dx.doi.org/10.1074/jbc.M301226200
   PubMed Web of Science ®Google Scholar
• Hentschke M, Berneking L, Belmar Campos C, Buck F, Ruckdeschel K, Aepfelbacher M. Yersinia virulence factor YopM induces sustained RSK activation by interfering with dephosphorylation. PLoS One 2010; 5(10):e13165; PMID:20957203; http://dx.doi.org/10.1371/journal.pone.0013165
   PubMed Web of Science ®Google Scholar
• Chung LK, Park YH, Zheng Y, Brodsky IE, Hearing P, Kastner DL, Chae JJ, Bliska JB. The Yersinia virulence factor YopM hijacks host kinases to inhibit type III effector-triggered activation of the pyrin inflammasome. Cell Host Microbe 2016; 20(3):296-306; PMID:27569559; http://dx.doi.org/10.1016/j.chom.2016.07.018
   PubMed Web of Science ®Google Scholar
• Berneking L, Schnapp M, Rumm A, Trasak C, Ruckdeschel K, Alawi M, Grundhoff A, Kikhney AG, Koch-Nolte F, Buck F, et al. Immunosuppressive Yersinia effector YopM binds DEAD Box helicase DDX3 to control ribosomal S6 kinase in the nucleus of host cells. PLoS Pathog 2016; 12(6):e1005660; PMID:27300509; http://dx.doi.org/10.1371/journal.ppat.1005660
   PubMed Web of Science ®Google Scholar
• Chung LK, Philip NH, Schmidt VA, Koller A, Strowig T, Flavell RA, Brodsky IE, Bliska JB. IQGAP1 is important for activation of caspase-1 in macrophages and is targeted by Yersinia pestis type III effector YopM. mBio 2014; 5(4):e01402-14; PMID:24987096; http://dx.doi.org/10.1128/mBio.01402-14
   PubMed Web of Science ®Google Scholar
• LaRock CN, Cookson BT. The Yersinia virulence effector YopM binds caspase-1 to arrest inflammasome assembly and processing. Cell Host Microbe 2012; 12(6):799-805; PMID:23245324; http://dx.doi.org/10.1016/j.chom.2012.10.020
   PubMed Web of Science ®Google Scholar
• McCoy MW, Marré ML, Lesser CF, Mecsas J. The C-terminal tail of Yersinia pseudotuberculosis YopM Is critical for interacting with RSK1 and for virulence. Infect Immun 2010; 78(6):2584-98; PMID:20368345; http://dx.doi.org/10.1128/IAI.00141-10
   PubMed Web of Science ®Google Scholar
• McPhee JB, Mena P, Bliska JB. Delineation of regions of the Yersinia YopM protein required for interaction with the RSK1 and PRK2 host kinases and their requirement for interleukin-10 production and virulence. Infect Immun 2010; 78(8):3529-39; PMID:20515922; http://dx.doi.org/10.1128/IAI.00269-10
   PubMed Web of Science ®Google Scholar
• Kerschen EJ, Cohen DA, Kaplan AM, Straley SC. The plague virulence protein YopM targets the innate immune response by causing a global depletion of NK cells. Infect Immun 2004; 72(8):4589-4602; PMID:15271919; http://dx.doi.org/10.1128/IAI.72.8.4589-4602.2004
   PubMed Web of Science ®Google Scholar
• Ye Z, Gorman AA, Uittenbogaard AM, Myers-Morales T, Kaplan AM, Cohen DA, Straley SC. Caspase-3 mediates the pathogenic effect of Yersinia pestis YopM in liver of C57BL/6 mice and contributes to YopM's function in spleen. PLoS One 2014; 9(11):e110956; PMID:25372388; http://dx.doi.org/10.1371/journal.pone.0110956
   PubMed Web of Science ®Google Scholar
• Stasulli NM, Eichelberger KR, Price PA, Pechous RD, Montgomery SA, Parker JS, Goldman WE. Spatially distinct neutrophil responses within the inflammatory lesions of pneumonic plague. mBio 2015; 6(5):e01530-15; PMID:26463167; http://dx.doi.org/10.1128/mBio.01530-15
   PubMed Web of Science ®Google Scholar
• Rüter C, Schmidt MA, inventors; Westfälische Wilhelms-Universität Münster, assignee. Yersinia Outer Protein M (YopM) in the Treatment of Psoriasis. US20160095898 A1 2014 Jul 30
   Google Scholar
• Rüter C, Heusipp G, Schmidt MA, inventors; Universitätsklinikum Münster, assignee. YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions. 2014 US8840901 B2
   Google Scholar
• Nograles KE, Krueger JG. Anti-cytokine therapies for psoriasis. Exp Cell Res 2011; 317(9):1293-1300; PMID:21300061; http://dx.doi.org/10.1016/j.yexcr.2011.01.024
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. J Am Acad Dermatol 2016; 75(3):612-618.e6; PMID:27061047; http://dx.doi.org/10.1016/j.jaad.2016.02.1221
   PubMed Web of Science ®Google Scholar
• Mahdavi A, Szychowski J, Ngo JT, Sweredoski MJ, Graham RLJ, Hess S, Schneewind O, Mazmanian SK, Tirrell DA. Identification of secreted bacterial proteins by noncanonical amino acid tagging. Proc Natl Acad Sci U S A 2014; 111(1):433-8; PMID:24347637; http://dx.doi.org/10.1073/pnas.1301740111
   PubMed Web of Science ®Google Scholar
• Rosqvist R, Forsberg A, Rimpilainen M, Bergman T, Wolf-Watz H. The cytotoxic protein YopE of Yersinia obstructs the primary host defence. Mol Microbiol 1990; 4(4):657-67; PMID:2191183; http://dx.doi.org/10.1111/j.1365-2958.1990.tb00635.x
   PubMed Web of Science ®Google Scholar
• Viboud GI, Bliska JB. A bacterial type III secretion system inhibits actin polymerization to prevent pore formation in host cell membranes. EMBO J 2001; 20(19):5373-82; PMID:11574469; http://dx.doi.org/10.1093/emboj/20.19.5373
   PubMed Web of Science ®Google Scholar
• Andor A, Trulzsch K, Essler M, Roggenkamp A, Wiedemann A, Heesemann J, Aepfelbacher M. YopE of Yersinia, a GAP for Rho GTPases, selectively modulates Rac-dependent actin structures in endothelial cells. Cell Microbiol 2001; 3(5):301-10; PMID:11298653; http://dx.doi.org/10.1046/j.1462-5822.2001.00114.x
   PubMed Web of Science ®Google Scholar
• Mohammadi S, Isberg RR. Yersinia pseudotuberculosis virulence determinants invasin, YopE, and YopT modulate RhoG activity and localization. Infect Immun 2009; 77(11):4771-82; PMID:19720752; http://dx.doi.org/10.1128/IAI.00850-09
   PubMed Web of Science ®Google Scholar
• Black DS, Bliska JB. The RhoGAP activity of the Yersinia pseudotuberculosis cytotoxin YopE is required for antiphagocytic function and virulence. Mol Microbiol 2000; 37(3):515-27; PMID:10931345; http://dx.doi.org/10.1046/j.1365-2958.2000.02021.x
   PubMed Web of Science ®Google Scholar
• Evdokimov AG, Tropea JE, Routzahn KM, Waugh DS. Crystal structure of the Yersinia pestis GTPase activator YopE. Protein Sci 2002; 11(2):401-8; PMID:11790850; http://dx.doi.org/10.1110/ps.34102
   PubMed Web of Science ®Google Scholar
• Boyd AP, Lambermont I, Cornelis GR. Competition between the Yops of Yersinia enterocolitica for delivery into eukaryotic cells: Role of the SycE chaperone binding domain of YopE. J Bacteriol 2000; 182(17):4811-21; PMID:10940022; http://dx.doi.org/10.1128/JB.182.17.4811-4821.2000
   PubMed Web of Science ®Google Scholar
• Krall R, Zhang Y, Barbieri JT. Intracellular membrane localization of Pseudomonas ExoS and Yersinia YopE in mammalian cells. J Biol Chem 2004; 279(4):2747-53; PMID:14597627; http://dx.doi.org/10.1074/jbc.M301963200
   PubMed Web of Science ®Google Scholar
• Ruckdeschel K, Pfaffinger G, Trulzsch K, Zenner G, Richter K, Heesemann J, Aepfelbacher M. The proteasome pathway destabilizes Yersinia outer protein E and represses its antihost cell activities. J Immunol 2006; 176(10):6093-6102; PMID:16670318; http://dx.doi.org/10.4049/jimmunol.176.10.6093
   PubMed Web of Science ®Google Scholar
• Hentschke M, Trülzsch K, Heesemann J, Aepfelbacher M, Ruckdeschel K. Serogroup-related escape of Yersinia enterocolitica YopE from degradation by the ubiquitin-proteasome pathway. Infect Immun 2007; 75(9):4423-31; PMID:17606597; http://dx.doi.org/10.1128/IAI.00528-07
   PubMed Web of Science ®Google Scholar
• Aili M, Isaksson EL, Carlsson SE, Wolf-Watz H, Rosqvist R, Francis MS. Regulation of Yersinia Yop-effector delivery by translocated YopE. Int J Med Microbiol 2008; 298(3–4):183-92; PMID:17597003; http://dx.doi.org/10.1016/j.ijmm.2007.04.007
   PubMed Web of Science ®Google Scholar
• Gaus K, Hentschke M, Czymmeck N, Novikova L, Trülzsch K, Valentin-Weigand P, Aepfelbacher M, Ruckdeschel K. Destabilization of YopE by the ubiquitin-proteasome pathway fine-tunes Yop delivery into host cells and facilitates systemic spread of Yersinia enterocolitica in host lymphoid tissue. Infect Immun 2011; 79(3):1166-75; PMID:21149597; http://dx.doi.org/10.1128/IAI.00694-10
   PubMed Web of Science ®Google Scholar
• Lockman HA, Gillespie RA, Baker BD, Shakhnovich E. Yersinia pseudotuberculosis produces a cytotoxic necrotizing factor. Infect Immun 2002; 70(5):2708-14; PMID:11953417; http://dx.doi.org/10.1128/IAI.70.5.2708-2714.2002
   PubMed Web of Science ®Google Scholar
• Wolters M, Boyle EC, Lardong K, Truelzsch K, Steffen A, Rottner K, Ruckdeschel K, Aepfelbacher M. Cytotoxic necrotizing factor-Y boosts Yersinia effector translocation by activating Rac. J Biol Chem 2013; 288(32):23543-53; PMID:23803609; http://dx.doi.org/10.1074/jbc.M112.448662
   PubMed Web of Science ®Google Scholar
• Bliska JB, Wang X, Viboud GI, Brodsky IE. Modulation of innate immune responses by Yersinia type III secretion system translocators and effectors. Cell Microbiol 2013; 15(10):1622-31; PMID:23834311; http://dx.doi.org/10.1111/cmi.12164
   PubMed Web of Science ®Google Scholar
• Mainiero F, Soriani A, Strippoli R, Jacobelli J, Gismondi A, Piccoli M, Frati L, Santoni A. RAC1/P38 MAPK signaling pathway controls beta1 integrin-induced interleukin-8 production in human natural killer cells. Immunity 2000; 12(1):7-16; PMID:10661401; http://dx.doi.org/10.1016/S1074-7613(00)80154-5
   PubMed Web of Science ®Google Scholar
• Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995; 81(7):1137-46; PMID:7600581; http://dx.doi.org/10.1016/S0092-8674(05)80018-2
   PubMed Web of Science ®Google Scholar
• Viboud GI, Mejía E, Bliska JB. Comparison of YopE and YopT activities in counteracting host signalling responses to Yersinia pseudotuberculosis infection. Cell Microbiol 2006; 8(9):1504-15; PMID:16922868; http://dx.doi.org/10.1111/j.1462-5822.2006.00729.x
   PubMed Web of Science ®Google Scholar
• Schotte P, Denecker G, van Den Broeke A, Vandenabeele P, Cornelis GR, Beyaert R. Targeting Rac1 by the Yersinia effector protein YopE inhibits caspase-1-mediated maturation and release of interleukin-1beta. J Biol Chem 2004; 279(24):25134-42; PMID:15060067; http://dx.doi.org/10.1074/jbc.M401245200
   PubMed Web of Science ®Google Scholar
• Condliffe AM, Webb LMC, Ferguson GJ, Davidson K, Turner M, Vigorito E, Manifava M, Chilvers ER, Stephens LR, Hawkins PT. RhoG regulates the neutrophil NADPH oxidase. J Immunol 2006; 176(9):5314-20; PMID:16621998; http://dx.doi.org/10.4049/jimmunol.176.9.5314
   PubMed Web of Science ®Google Scholar
• Hordijk PL. Regulation of NADPH oxidases: The role of Rac proteins. Circ Res 2006; 98(4):453-62; PMID:16514078; http://dx.doi.org/10.1161/01.RES.0000204727.46710.5e
   PubMed Web of Science ®Google Scholar
• Songsungthong W, Higgins MC, Rolán HG, Murphy JL, Mecsas J. ROS-inhibitory activity of YopE is required for full virulence of Yersinia in mice. Cell Microbiol 2010; 12(7):988-1001; PMID:20148901; http://dx.doi.org/10.1111/j.1462-5822.2010.01448.x
   PubMed Web of Science ®Google Scholar
• Conlan JW. Critical roles of neutrophils in host defense against experimental systemic infections of mice by Listeria monocytogenes, Salmonella typhimurium, and Yersinia enterocolitica. Infect Immun 1997; 65(2):630-5; PMID:9009323
   PubMed Web of Science ®Google Scholar
• Westermark L, Fahlgren A, Fällman M. Yersinia pseudotuberculosis efficiently escapes polymorphonuclear neutrophils during early infection. Infect Immun 2014; 82(3):1181-91; PMID:24379291; http://dx.doi.org/10.1128/IAI.01634-13
   PubMed Web of Science ®Google Scholar
• Wang X, Parashar K, Sitaram A, Bliska JB. The GAP activity of type III effector YopE triggers killing of Yersinia in macrophages. PLoS Pathog 2014; 10(8):e1004346; PMID:25165815; http://dx.doi.org/10.1371/journal.ppat.1004346
   PubMed Web of Science ®Google Scholar
• Schulz A. Influence of Rho GTPases on Toll-Like Receptor (TLR)–induced cytokine production of murine macrophages [Dissertation]. Osnabrück, Germany: Universität Osnabrück; 2014
   Google Scholar
• Fessler MB, Arndt PG, Just I, Nick JA, Malcolm KC, Scott Worthen G. Dual role for RhoA in suppression and induction of cytokines in the human neutrophil. Blood 2007; 109(3):1248-56; PMID:17018860; http://dx.doi.org/10.1182/blood-2006-03-012898
   PubMed Web of Science ®Google Scholar
• Kuhl AA, Kakirman H, Janotta M, Dreher S, Cremer P, Pawlowski NN, Loddenkemper C, Heimesaat MM, Grollich K, Zeitz M, et al. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology 2007; 133(6):1882-92; PMID:18054560; http://dx.doi.org/10.1053/j.gastro.2007.08.073
   PubMed Web of Science ®Google Scholar
• Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013; 31(3–4):336-44; PMID:24246984; http://dx.doi.org/10.1159/000354689
   PubMed Web of Science ®Google Scholar
• Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: From mechanisms to disease. Annu Rev Immunol 2012; 30:459-89; PMID:22224774; http://dx.doi.org/10.1146/annurev-immunol-020711-074942
   PubMed Web of Science ®Google Scholar
• Biro M, Munoz MA, Weninger W. Targeting Rho-GTPases in immune cell migration and inflammation. Br J Pharmacol 2014; 171(24):5491-5506; PMID:24571448; http://dx.doi.org/10.1111/bph.12658
   PubMed Web of Science ®Google Scholar
• Larmonier CB, Midura-Kiela MT, Ramalingam R, Laubitz D, Janikashvili N, Larmonier N, Ghishan FK, Kiela PR. Modulation of neutrophil motility by curcumin. Inflamm Bowel Dis 2011; 17(2):503-15; PMID:20629184; http://dx.doi.org/10.1002/ibd.21391
   PubMed Web of Science ®Google Scholar
• Boppana NB, Devarajan A, Gopal K, Barathan M, Bakar SA, Shankar EM, Ebrahim AS, Farooq SM. Blockade of CXCR2 signalling: A potential therapeutic target for preventing neutrophil-mediated inflammatory diseases. Exp Biol Med 2014; 239(5):509-18; PMID:24625439; http://dx.doi.org/10.1177/1535370213520110
   PubMed Web of Science ®Google Scholar
• Shioya Y, Katakura K, Ohira H. Neutrophil elastase inhibitor suppresses IL-17 based inflammation of murine experimental colitis. Fukushima J Med Sci 2014; 60(1):14-21; PMID:24670675; http://dx.doi.org/10.5387/fms.2013-2
   PubMedGoogle Scholar
• Huang Y, Xiao S, Jiang Q. Role of Rho kinase signal pathway in inflammatory bowel disease. Int J Clin Exp Med 2015; 8(3):3089-97; PMID:26064197
   PubMed Web of Science ®Google Scholar
• Beyaert R, Schotte P, inventors; Vib Vzw, Universiteit Gent, assignee. The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors. WO 2004064713 A2. 2004 Aug 5
   Google Scholar
• Iriarte M, Cornelis GR. YopT, a new Yersinia Yop effector protein, affects the cytoskeleton of host cells. Mol Microbiol 1998; 29(3):915-29; PMID:9723929; http://dx.doi.org/10.1046/j.1365-2958.1998.00992.x
   PubMed Web of Science ®Google Scholar
• Shao F, Vacratsis PO, Bao ZQ, Bowers KE, Fierke CA, Dixon JE. Biochemical characterization of the Yersinia YopT protease: Cleavage site and recognition elements in Rho GTPases. Proc Natl Acad Sci U S A 2003; 100(3):904-9; PMID:12538863; http://dx.doi.org/10.1073/pnas.252770599
   PubMed Web of Science ®Google Scholar
• Sorg I, Goehring UM, Aktories K, Schmidt G. Recombinant Yersinia YopT leads to uncoupling of RhoA-effector interaction. Infect Immun 2001; 69(12):7535-43; PMID:11705930; http://dx.doi.org/10.1128/IAI.69.12.7535-7543.2001
   PubMed Web of Science ®Google Scholar
• Füller F, Bergo MO, Young SG, Aktories K, Schmidt G. Endoproteolytic processing of RhoA by Rce1 is required for the cleavage of RhoA by Yersinia enterocolitica outer protein T. Infect Immun 2006; 74(3):1712-7; PMID:16495543; http://dx.doi.org/10.1128/IAI.74.3.1712-1717.2006
   PubMed Web of Science ®Google Scholar
• Aepfelbacher M, Trasak C, Wilharm G, Wiedemann A, Trulzsch K, Krauss K, Gierschik P, Heesemann J. Characterization of YopT effects on Rho GTPases in Yersinia enterocolitica-infected cells. J Biol Chem 2003; 278(35):33217-23; PMID:12791693; http://dx.doi.org/10.1074/jbc.M303349200
   PubMed Web of Science ®Google Scholar
• Shao F, Merritt PM, Bao ZQ, Innes RW, Dixon JE. A Yersinia effector and a Pseudomonas avirulence protein define a family of cysteine proteases functioning in bacterial pathogenesis. Cell 2002; 109(5):575-88; PMID:12062101; http://dx.doi.org/10.1016/S0092-8674(02)00766-3
   PubMed Web of Science ®Google Scholar
• Zhu M, Shao F, Innes RW, Dixon JE, Xu Z. The crystal structure of Pseudomonas avirulence protein AvrPphB: A papain-like fold with a distinct substrate-binding site. Proc Natl Acad Sci U S A 2004; 101(1):302-7; PMID:14694194; http://dx.doi.org/10.1073/pnas.2036536100
   PubMed Web of Science ®Google Scholar
• Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8(2):47-52; PMID:8858389
   PubMedGoogle Scholar
• Dai Y, Chitaley K, Webb RC, Lewis RW, Mills TM. Topical application of a Rho-kinase inhibitor in rats causes penile erection. Int J Impot Res 2004; 16(3):294-8; PMID:14961052; http://dx.doi.org/10.1038/sj.ijir.3901171
   PubMed Web of Science ®Google Scholar
• He Y, Xu H, Liang L, Zhan Z, Yang X, Yu X, Ye Y, Sun L. Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum 2008; 58(11):3366-76; PMID:18975348; http://dx.doi.org/10.1002/art.23986
   PubMed Web of Science ®Google Scholar
• Tan EYM, Law JWS, Wang C, Lee AYW. Development of a cell transducible RhoA inhibitor TAT-C3 transferase and its encapsulation in biocompatible microspheres to promote survival and enhance regeneration of severed neurons. Pharm Res 2007; 24(12):2297-2308; PMID:17899323; http://dx.doi.org/10.1007/s11095-007-9454-6
   PubMed Web of Science ®Google Scholar
• Lord-Fontaine S, Yang F, Diep Q, Dergham P, Munzer S, Tremblay P, McKerracher L. Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J Neurotrauma 2008; 25(11):1309-22; PMID:19061375; http://dx.doi.org/10.1089/neu.2008.0613
   PubMed Web of Science ®Google Scholar
• Huentelman MJ, Stephan DA, Talboom J, Corneveaux JJ, Reiman DM, Gerber JD, Barnes CA, Alexander GE, Reiman EM, Bimonte-Nelson HA. Peripheral delivery of a ROCK inhibitor improves learning and working memory. Behav Neurosci 2009; 123(1):218-23; PMID:19170447; http://dx.doi.org/10.1037/a0014260
   PubMed Web of Science ®Google Scholar
• Galyov EE, Håkansson S, Forsberg A, Wolf-Watz H. A secreted protein kinase of Yersinia pseudotuberculosis is an indispensable virulence determinant. Nature 1993; 361(6414):730-2; PMID:8441468; http://dx.doi.org/10.1038/361730a0
   PubMed Web of Science ®Google Scholar
• Håkansson S, Galyov EE, Rosqvist R, Wolf-Watz H. The Yersinia YpkA Ser/Thr kinase is translocated and subsequently targeted to the inner surface of the HeLa cell plasma membrane. Mol Microbiol 1996; 20(3):593-603; PMID:8736538; http://dx.doi.org/10.1046/j.1365-2958.1996.5251051.x
   PubMed Web of Science ®Google Scholar
• Juris SJ, Rudolph AE, Huddler D, Orth K, Dixon JE. A distinctive role for the Yersinia protein kinase: Actin binding, kinase activation, and cytoskeleton disruption. Proc Natl Acad Sci U S A 2000; 97(17):9431-6; PMID:10920208; http://dx.doi.org/10.1073/pnas.170281997
   PubMed Web of Science ®Google Scholar
• Lee WL, Grimes JM, Robinson RC. Yersinia effector YopO uses actin as bait to phosphorylate proteins that regulate actin polymerization. Nat Struct Mol Biol 2015; 22(3):248-55; PMID:25664724; http://dx.doi.org/10.1038/nsmb.2964
   PubMed Web of Science ®Google Scholar
• Navarro L, Koller A, Nordfelth R, Wolf-Watz H, Taylor S, Dixon JE. Identification of a molecular target for the Yersinia protein kinase A. Mol Cell 2007; 26(4):465-77; PMID:17531806; http://dx.doi.org/10.1016/j.molcel.2007.04.025
   PubMed Web of Science ®Google Scholar
• Yang H, Ke Y, Wang J, Tan Y, Myeni SK, Li D, Shi Q, Yan Y, Chen H, Guo Z, et al. Insight into bacterial virulence mechanisms against host immune response via the Yersinia pestis-human protein-protein interaction network. Infect Immun 2011; 79(11):4413-24; PMID:21911467; http://dx.doi.org/10.1128/IAI.05622-11
   PubMed Web of Science ®Google Scholar
• Prehna G, Ivanov MI, Bliska JB, Stebbins CE. Yersinia virulence depends on mimicry of host Rho-family nucleotide dissociation inhibitors. Cell 2006; 126(5):869-80; PMID:16959567; http://dx.doi.org/10.1016/j.cell.2006.06.056
   PubMed Web of Science ®Google Scholar
• Nejedlik L, Pierfelice T, Geiser JR. Actin distribution is disrupted upon expression of Yersinia YopO/YpkA in yeast. Yeast 2004; 21(9):759-68; PMID:15282799; http://dx.doi.org/10.1002/yea.1135
   PubMed Web of Science ®Google Scholar
• Dukuzumuremyi JM, Rosqvist R, Hallberg B, Akerström B, Wolf-Watz H, Schesser K. The Yersinia protein kinase A is a host factor inducible RhoA/Rac-binding virulence factor. J Biol Chem 2000; 275(45):35281-90; PMID:10950948; http://dx.doi.org/10.1074/jbc.M003009200
   PubMed Web of Science ®Google Scholar
• Niedergang F, Chavrier P. Regulation of phagocytosis by Rho GTPases. Curr Top Microbiol Immunol 2005; 291:43-60; PMID:15981459
   PubMed Web of Science ®Google Scholar
• Galvez J. Role of Th17 Cells in the pathogenesis of human IBD. ISRN Inflamm 2014; 2014:928461; PMID:25101191; http://dx.doi.org/10.1155/2014/928461
   PubMedGoogle Scholar
• Liu Y, Wang D, Li F, Shi G. Galphaq controls rheumatoid arthritis via regulation of Th17 differentiation. Immunol Cell Biol 2015; 93(7):616-24; PMID:25732870; http://dx.doi.org/10.1038/icb.2015.13
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Taniguchi M, Moritani Y, Hayashi K, Saito T, Takasaki J, Nagai K, Inagaki O, Shikama H. Antithrombotic and thrombolytic efficacy of YM-254890, a G q/11 inhibitor, in a rat model of arterial thrombosis. Thromb Haemost 2003; 90(3):406-13; PMID:12958608; http://dx.doi.org/10.1160/TH03-02-0115
   PubMed Web of Science ®Google Scholar
• Zaima K, Deguchi J, Matsuno Y, Kaneda T, Hirasawa Y, Morita H. Vasorelaxant effect of FR900359 from Ardisia crenata on rat aortic artery. J Nat Med 2013; 67(1):196-201; PMID:22388972; http://dx.doi.org/10.1007/s11418-012-0644-0
   PubMed Web of Science ®Google Scholar
• Richter K. Charakterisierung der molekularen Wirkungen des Y. enterocolitica Effektorproteins YopP auf die Wirtszelle [Dissertation]. München, Germany: Ludwig Maximilians-Universität; 2004
   Google Scholar
• Brodsky IE, Medzhitov R. Reduced secretion of YopJ by Yersinia limits in vivo cell death but enhances bacterial virulence. PLoS Pathog 2008; 4(5):e1000067; PMID:18483548; http://dx.doi.org/10.1371/journal.ppat.1000067
   PubMed Web of Science ®Google Scholar
• Zheng Y, Lilo S, Brodsky IE, Zhang Y, Medzhitov R, Marcu KB, Bliska JB. A Yersinia effector with enhanced inhibitory activity on the NF-κB pathway activates the NLRP3/ASC/caspase-1 inflammasome in macrophages. PLoS Pathog 2011; 7(4):e1002026; PMID:21533069; http://dx.doi.org/10.1371/journal.ppat.1002026
   PubMed Web of Science ®Google Scholar
• Zheng Y, Lilo S, Mena P, Bliska JB. YopJ-induced caspase-1 activation in Yersinia-infected macrophages: Independent of apoptosis, linked to necrosis, dispensable for innate host defense. PLoS One 2012; 7(4):e36019; PMID:22563435; http://dx.doi.org/10.1371/journal.pone.0036019
   PubMed Web of Science ®Google Scholar
• Zauberman A, Tidhar A, Levy Y, Bar-Haim E, Halperin G, Flashner Y, Cohen S, Shafferman A, Mamroud E. Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS One 2009; 4(6):e5938; PMID:19529770; http://dx.doi.org/10.1371/journal.pone.0005938
   PubMed Web of Science ®Google Scholar
• Sweet CR, Conlon J, Golenbock DT, Goguen J, Silverman N. YopJ targets TRAF proteins to inhibit TLR-mediated NF-kappaB, MAPK and IRF3 signal transduction. Cell Microbiol 2007; 9(11):2700-15; PMID:17608743; http://dx.doi.org/10.1111/j.1462-5822.2007.00990.x
   PubMed Web of Science ®Google Scholar
• Zhou H, Monack DM, Kayagaki N, Wertz I, Yin J, Wolf B, Dixit VM. Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J Exp Med 2005; 202(10):1327-32; PMID:16301742; http://dx.doi.org/10.1084/jem.20051194
   PubMed Web of Science ®Google Scholar
• Cao Y, Guan K, He X, Wei C, Zheng Z, Zhang Y, Ma S, Zhong H, Shi W. Yersinia YopJ negatively regulates IRF3-mediated antibacterial response through disruption of STING-mediated cytosolic DNA signaling. Biochim Biochim Biophys Acta 2016; 1863(12):3148-59; PMID:27742471; http://dx.doi.org/10.1016/j.bbamcr.2016.10.004
   PubMed Web of Science ®Google Scholar
• Haase R, Richter K, Pfaffinger G, Courtois G, Ruckdeschel K. Yersinia outer protein P suppresses TGF-beta-activated kinase-1 activity to impair innate immune signaling in Yersinia enterocolitica-infected cells. J Immunol 2005; 175(12):8209-17; PMID:16339560; http://dx.doi.org/10.4049/jimmunol.175.12.8209
   PubMed Web of Science ®Google Scholar
• Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103(2):351-61; PMID:11057907; http://dx.doi.org/10.1016/S0092-8674(00)00126-4
   PubMed Web of Science ®Google Scholar
• Shi C, Kehrl JH. Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). J Biol Chem 2003; 278(17):15429-34; PMID:12591926; http://dx.doi.org/10.1074/jbc.M211796200
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu M, Wang Y, Shu H. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. J Biol Chem 2012; 287(34):28646-55; PMID:22745133; http://dx.doi.org/10.1074/jbc.M112.362608
   PubMed Web of Science ®Google Scholar
• Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995; 9(13):1586-97; PMID:7628694; http://dx.doi.org/10.1101/gad.9.13.1586
   PubMed Web of Science ®Google Scholar
• Häcker H, Tseng P, Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 2011; 11(7):457-68; PMID:21660053; http://dx.doi.org/10.1038/nri2998
   PubMed Web of Science ®Google Scholar
• Mittal R, Peak-Chew S, McMahon HT. Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc Natl Acad Sci U S A 2006; 103(49):18574-9; PMID:17116858; http://dx.doi.org/10.1073/pnas.0608995103
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ, Orth K. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 2006; 312(5777):1211-4; PMID:16728640; http://dx.doi.org/10.1126/science.1126867
   PubMed Web of Science ®Google Scholar
• Meinzer U, Barreau F, Esmiol-Welterlin S, Jung C, Villard C, Léger T, Ben-Mkaddem S, Berrebi D, Dussaillant M, Alnabhani Z, et al. Yersinia pseudotuberculosis effector YopJ subverts the Nod2/RICK/TAK1 pathway and activates caspase-1 to induce intestinal barrier dysfunction. Cell Host Microbe 2012; 11(4):337-51; PMID:22520462; http://dx.doi.org/10.1016/j.chom.2012.02.009
   PubMed Web of Science ®Google Scholar
• Paquette N, Conlon J, Sweet C, Rus F, Wilson L, Pereira A, Rosadini CV, Goutagny N, Weber ANR, Lane WS, et al. Serine/threonine acetylation of TGFβ-activated kinase (TAK1) by Yersinia pestis YopJ inhibits innate immune signaling. Proc Natl Acad Sci U S A 2012; 109(31):12710-5; PMID:22802624; http://dx.doi.org/10.1073/pnas.1008203109
   PubMed Web of Science ®Google Scholar
• Thiefes A, Wolf A, Doerrie A, A Grassl G, Matsumoto K, Autenrieth IB, Bohn E, Sakurai H, Niedenthal R, Resch K, et al. The Yersinia enterocolitica effector YopP inhibits host cell signalling by inactivating the protein kinase TAK1 in the IL-1 signalling pathway. EMBO Rep 2006; 7(8):838-44; PMID:16845370; http://dx.doi.org/10.1038/sj.embor.7400754
   PubMed Web of Science ®Google Scholar
• Orth K, Palmer LE, Bao ZQ, Stewart S, Rudolph AE, Bliska JB, Dixon JE. Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector. Science 1999; 285(5435):1920-3; PMID:10489373; http://dx.doi.org/10.1126/science.285.5435.1920
   PubMed Web of Science ®Google Scholar
• Pruneda JN, Durkin CH, Geurink PP, Ovaa H, Santhanam B, Holden DW, Komander D. The molecular basis for ubiquitin and ubiquitin-like specificities in bacterial effector proteases. Mol Cell 2016; 63(2):271-6; PMID:27425412; http://dx.doi.org/10.1016/j.molcel.2016.06.015
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ma K, Yuan S, Luo Y, Jiang S, Hawara E, Pan S, Ma W, Song J. Structure of a pathogen effector reveals the enzymatic mechanism of a novel acetyltransferase family. Nat Struct Mol Biol 2016; 23(9):847-52; PMID:27525589; http://dx.doi.org/10.1038/nsmb.3279
   PubMed Web of Science ®Google Scholar
• Mittal R, Peak-Chew SY, Sade RS, Vallis Y, McMahon HT. The acetyltransferase activity of the bacterial toxin YopJ of Yersinia is activated by eukaryotic host cell inositol hexakisphosphate. J Biol Chem 2010; 285(26):19927-34; PMID:20430892; http://dx.doi.org/10.1074/jbc.M110.126581
   PubMed Web of Science ®Google Scholar
• Ajibade AA, Wang HY, Wang R. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol 2013; 34(7):307-16; PMID:23664135; http://dx.doi.org/10.1016/j.it.2013.03.007
   PubMed Web of Science ®Google Scholar
• Yoon S, Liu Z, Eyobo Y, Orth K. Yersinia effector YopJ inhibits yeast MAPK signaling pathways by an evolutionarily conserved mechanism. J Biol Chem 2003; 278(4):2131-5; PMID:12433923; http://dx.doi.org/10.1074/jbc.M209905200
   PubMed Web of Science ®Google Scholar
• Rosadini CV, Zanoni I, Odendall C, Green ER, Paczosa MK, Philip NH, Brodsky IE, Mecsas J, Kagan JC. A single bacterial immune evasion strategy dismantles both MyD88 and TRIF signaling pathways downstream of TLR4. Cell Host Microbe 2015; 18(6):682-93; PMID:26651944; http://dx.doi.org/10.1016/j.chom.2015.11.006
   PubMed Web of Science ®Google Scholar
• Denecker G, Tötemeyer S, Mota LJ, Troisfontaines P, Lambermont I, Youta C, Stainier I, Ackermann M, Cornelis GR, Denecker G, et al. Effect of low- and high-virulence Yersinia enterocolitica strains on the inflammatory response of human umbilical vein endothelial cells. Infect Immun 2002; 70(7):3510-20; PMID:12065490; http://dx.doi.org/10.1128/IAI.70.7.3510-3520.2002
   PubMed Web of Science ®Google Scholar
• Boland AM, Cornelis GR. Role of YopP in suppression of tumor necrosis factor alpha release by macrophages during Yersinia infection. Infect Immun 1998; 66(5):1878-84; PMID:9573064
   PubMed Web of Science ®Google Scholar
• Autenrieth SE, Soldanova I, Rösemann R, Gunst D, Zahir N, Kracht M, Ruckdeschel K, Wagner H, Borgmann S, Autenrieth IB. Yersinia enterocolitica YopP inhibits MAP kinase-mediated antigen uptake in dendritic cells. Cell Microbiol 2007; 9(2):425-37; PMID:16953801; http://dx.doi.org/10.1111/j.1462-5822.2006.00800.x
   PubMed Web of Science ®Google Scholar
• Mills SD, Boland AM, Sory MP, van der Smissen P, Kerbourch C, Finlay BB, Cornelis GR. Yersinia enterocolitica induces apoptosis in macrophages by a process requiring functional type III secretion and translocation mechanisms and involving YopP, presumably acting as an effector protein. Proc Natl Acad Sci U S A 1997; 94(23):12638-43; PMID:9356502; http://dx.doi.org/10.1073/pnas.94.23.12638
   PubMed Web of Science ®Google Scholar
• Monack DM, Mecsas J, Ghori N, Falkow S. Yersinia signals macrophages to undergo apoptosis and YopJ is necessary for this cell death. Proc Natl Acad Sci U S A 1997; 94(19):10385-90; PMID:9294220; http://dx.doi.org/10.1073/pnas.94.19.10385
   PubMed Web of Science ®Google Scholar
• Ruckdeschel K, Roggenkamp A, Lafont V, Mangeat P, Heesemann J, Rouot B. Interaction of Yersinia enterocolitica with macrophages leads to macrophage cell death through apoptosis. Infect Immun 1997; 65(11):4813-21; PMID:9353070
   PubMed Web of Science ®Google Scholar
• Denecker G, Declercq W, Geuijen CA, Boland AM, Benabdillah R, van Gurp M, Sory MP, Vandenabeele P, Cornelis GR. Yersinia enterocolitica YopP-induced apoptosis of macrophages involves the apoptotic signaling cascade upstream of bid. J Biol Chem 2001; 276(23):19706-14; PMID:11279213; http://dx.doi.org/10.1074/jbc.M101573200
   PubMed Web of Science ®Google Scholar
• Erfurth SE, Gröbner S, Kramer U, Gunst DS, Soldanova I, Schaller M, Autenrieth IB, Borgmann S. Yersinia enterocolitica induces apoptosis and inhibits surface molecule expression and cytokine production in murine dendritic cells. Infect Immun 2004; 72(12):7045-54; PMID:15557628; http://dx.doi.org/10.1128/IAI.72.12.7045-7054.2004
   PubMed Web of Science ®Google Scholar
• Spinner JL, Seo KS, O'Loughlin JL, Cundiff JA, Minnich SA, Bohach GA, Kobayashi SD. Neutrophils are resistant to Yersinia YopJ/P-induced apoptosis and are protected from ROS-mediated cell death by the type III secretion system. PLoS One 2010; 5(2):e9279; PMID:20174624; http://dx.doi.org/10.1371/journal.pone.0009279
   PubMed Web of Science ®Google Scholar
• Koch I, Dach K, Heesemann J, Hoffmann R. Yersinia enterocolitica inactivates NK cells. Int J Med Microbiol 2013; 303(8):433-42; PMID:23810728; http://dx.doi.org/10.1016/j.ijmm.2013.05.004
   PubMed Web of Science ®Google Scholar
• Zhang Y, Bliska JB. Role of toll-like receptor signaling in the apoptotic response of macrophages to Yersinia infection. Infect Immun 2003; 71(3):1513-9; PMID:12595470; http://dx.doi.org/10.1128/IAI.71.3.1513-1519.2003
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ting AT, Marcu KB, Bliska JB. Inhibition of MAPK and NF-kappa B pathways is necessary for rapid apoptosis in macrophages infected with Yersinia. J Immunol 2005; 174(12):7939-49; PMID:15944300; http://dx.doi.org/10.4049/jimmunol.174.12.7939
   PubMed Web of Science ®Google Scholar
• Weng D, Marty-Roix R, Ganesan S, Proulx MK, Vladimer GI, Kaiser WJ, Mocarski ES, Pouliot K, Chan FK, Kelliher MA, et al. Caspase-8 and RIP kinases regulate bacteria-induced innate immune responses and cell death. Proc Natl Acad Sci U S A 2014; 111(20):7391-6; PMID:24799678; http://dx.doi.org/10.1073/pnas.1403477111
   PubMed Web of Science ®Google Scholar
• Philip NH, Dillon CP, Snyder AG, Fitzgerald P, Wynosky-Dolfi MA, Zwack EE, Hu B, Fitzgerald L, Mauldin EA, Copenhaver AM, et al. Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-κB and MAPK signaling. Proc Natl Acad Sci U S A 2014; 111(20):7385-90; PMID:24799700; http://dx.doi.org/10.1073/pnas.1403252111
   PubMed Web of Science ®Google Scholar
• Davignon J, Hayder M, Baron M, Boyer J, Constantin A, Apparailly F, Poupot R, Cantagrel A. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013; 52(4):590-8; PMID:23204551; http://dx.doi.org/10.1093/rheumatology/kes304
   PubMed Web of Science ®Google Scholar
• Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T, van Rooijen N, Stratis A, Renkl AC, Sunderkötter C, Wlaschek M, et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006; 116(8):2105-14; PMID:16886059; http://dx.doi.org/10.1172/JCI27180
   PubMed Web of Science ®Google Scholar
• Wang H, Peters T, Sindrilaru A, Scharffetter-Kochanek K. Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. J Invest Dermatol 2009; 129(5):1100-14; PMID:19242511; http://dx.doi.org/10.1038/jid.2009.43
   PubMed Web of Science ®Google Scholar
• Pettersson S, Wolf-Watz H, inventors; Karolinska Innovations Ab, assignee. Composition and methods for the treatment of inflammatory diseases. WO 1998056817 A1. 1998 Dec 17
   Google Scholar
• Wallach D, Appel E, inventors. Chimeric proteins comprising Yersinia Yop, their preparation and pharmaceutical compositions containing them. WO/2006/109303. 2006 Oct 19
   Google Scholar
• Herrera Estrada LP, Padmore TJ, Champion JA. Bacterial effector nanoparticles as breast cancer therapeutics. Mol Pharm 2016; 13(3):710-9; PMID:26800341; http://dx.doi.org/10.1021/acs.molpharmaceut.5b00377
   PubMed Web of Science ®Google Scholar
• Sajid A, Arora G, Singhal A, Kalia VC, Singh Y. Protein phosphatases of pathogenic bacteria: Role in physiology and virulence. Annu Rev Microbiol 2015; 69:527-47; PMID:26359969; http://dx.doi.org/10.1146/annurev-micro-020415-111342
   PubMed Web of Science ®Google Scholar
• Guan KL, Dixon JE. Protein tyrosine phosphatase activity of an essential virulence determinant in Yersinia. Science 1990; 249(4968):553-6; PMID:2166336; http://dx.doi.org/10.1126/science.2166336
   PubMed Web of Science ®Google Scholar
• Sory MP, Boland AM, Lambermont I, Cornelis GR. Identification of the YopE and YopH domains required for secretion and internalization into the cytosol of macrophages, using the cyaA gene fusion approach. Proc Natl Acad Sci U S A 1995; 92(26):11998-12002; PMID:8618831; http://dx.doi.org/10.1073/pnas.92.26.11998
   PubMed Web of Science ®Google Scholar
• Smith CL, Khandelwal P, Keliikuli K, Zuiderweg ER, Saper MA. Structure of the type III secretion and substrate-binding domain of Yersinia YopH phosphatase. Mol Microbiol 2001; 42(4):967-79; PMID:11737640; http://dx.doi.org/10.1046/j.0950-382x.2001.02711.x
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Wang Y, Wu L, Fauman EB, Stuckey JA, Schubert HL, Saper MA, Dixon JE. The Cys(X)5Arg catalytic motif in phosphoester hydrolysis. Biochemistry 1994; 33(51):15266-70; PMID:7803389; http://dx.doi.org/10.1021/bi00255a007
   PubMed Web of Science ®Google Scholar
• Stuckey JA, Schubert HL, Fauman EB, Zhang ZY, Dixon JE, Saper MA. Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 A and the complex with tungstate. Nature 1994; 370(6490):571-5; PMID:8052312; http://dx.doi.org/10.1038/370571a0
   PubMed Web of Science ®Google Scholar
• Hu X, Stebbins CE. Dynamics of the WPD loop of the Yersinia protein tyrosine phosphatase. Biophys J 2006; 91(3):948-56; PMID:16698773; http://dx.doi.org/10.1529/biophysj.105.080259
   PubMed Web of Science ®Google Scholar
• Bliska JB, Clemens JC, Dixon JE, Falkow S. The Yersinia tyrosine phosphatase: Specificity of a bacterial virulence determinant for phosphoproteins in the J774A.1 macrophage. J Exp Med 1992; 176(6):1625-30; PMID:1281213; http://dx.doi.org/10.1084/jem.176.6.1625
   PubMed Web of Science ®Google Scholar
• Alonso A, Bottini N, Bruckner S, Rahmouni S, Williams S, Schoenberger SP, Mustelin T. Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH. J Biol Chem 2004; 279(6):4922-8; PMID:14623872; http://dx.doi.org/10.1074/jbc.M308978200
   PubMed Web of Science ®Google Scholar
• Persson C, Nordfelth R, Andersson K, Forsberg A, Wolf-Watz H, Fällman M. Localization of the Yersinia PTPase to focal complexes is an important virulence mechanism. Mol Microbiol 1999; 33(4):828-38; PMID:10447891; http://dx.doi.org/10.1046/j.1365-2958.1999.01529.x
   PubMed Web of Science ®Google Scholar
• Montagna LG, Ivanov MI, Bliska JB. Identification of residues in the N-terminal domain of the Yersinia tyrosine phosphatase that are critical for substrate recognition. J Biol Chem 2001; 276(7):5005-11; PMID:11069923; http://dx.doi.org/10.1074/jbc.M009045200
   PubMed Web of Science ®Google Scholar
• Adkins I, Köberle M, Gröbner S, Bohn E, Autenrieth IB, Borgmann S. Yersinia outer proteins E, H, P, and T differentially target the cytoskeleton and inhibit phagocytic capacity of dendritic cells. Int J Med Microbiol 2007; 297(4):235-44; PMID:17462949; http://dx.doi.org/10.1016/j.ijmm.2007.02.005
   PubMed Web of Science ®Google Scholar
• Fahlgren A, Westermark L, Akopyan K, Fällman M. Cell type-specific effects of Yersinia pseudotuberculosis virulence effectors. Cell Microbiol 2009; 11(12):1750-67; PMID:19681909; http://dx.doi.org/10.1111/j.1462-5822.2009.01365.x
   PubMed Web of Science ®Google Scholar
• Bruckner S, Rhamouni S, Tautz L, Denault J, Alonso A, Becattini B, Salvesen GS, Mustelin T. Yersinia phosphatase induces mitochondrially dependent apoptosis of T cells. J Biol Chem 2005; 280(11):10388-94; PMID:15632192; http://dx.doi.org/10.1074/jbc.M408829200
   PubMed Web of Science ®Google Scholar
• Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P. Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J 1999; 18(9):2459-71; PMID:10228160; http://dx.doi.org/10.1093/emboj/18.9.2459
   PubMed Web of Science ®Google Scholar
• Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006; 18(5):516-23; PMID:16919435; http://dx.doi.org/10.1016/j.ceb.2006.08.011
   PubMed Web of Science ®Google Scholar
• Ophir MJ, Liu BC, Bunnell SC. The N terminus of SKAP55 enables T cell adhesion to TCR and integrin ligands via distinct mechanisms. J Cell Biol 2013; 203(6):1021-41; PMID:24368808; http://dx.doi.org/10.1083/jcb.201305088
   PubMed Web of Science ®Google Scholar
• Isberg RR, Leong JM. Multiple beta 1 chain integrins are receptors for invasin, a protein that promotes bacterial penetration into mammalian cells. Cell 1990; 60(5):861-71; PMID:2311122; http://dx.doi.org/10.1016/0092-8674(90)90099-Z
   PubMed Web of Science ®Google Scholar
• Tran Van Nhieu G, Isberg RR. Bacterial internalization mediated by beta 1 chain integrins is determined by ligand affinity and receptor density. EMBO J 1993; 12(5):1887-95; PMID:8491181
   PubMed Web of Science ®Google Scholar
• Thinwa J, Segovia JA, Bose S, Dube PH. Integrin-mediated first signal for inflammasome activation in intestinal epithelial cells. J Immunol 2014; 193(3):1373-82; PMID:24965773; http://dx.doi.org/10.4049/jimmunol.1400145
   PubMed Web of Science ®Google Scholar
• Kampik D, Schulte R, Autenrieth IB. Yersinia enterocolitica invasin protein triggers differential production of interleukin-1, interleukin-8, monocyte chemoattractant protein 1, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor alpha in epithelial cells: Implications for understanding the early cytokine network in Yersinia infections. Infect Immun 2000; 68(5):2484-92; PMID:10768935; http://dx.doi.org/10.1128/IAI.68.5.2484-2492.2000
   PubMed Web of Science ®Google Scholar
• Bliska JB, Guan KL, Dixon JE, Falkow S. Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant. Proc Natl Acad Sci U S A 1991; 88(4):1187-91; PMID:1705028; http://dx.doi.org/10.1073/pnas.88.4.1187
   PubMed Web of Science ®Google Scholar
• Cantwell AM, Bubeck SS, Dube PH. YopH inhibits early pro-inflammatory cytokine responses during plague pneumonia. BMC Immunol 2010; 11:29; PMID:20565713; http://dx.doi.org/10.1186/1471-2172-11-29
   PubMed Web of Science ®Google Scholar
• Dave MN, Silva JE, Eliçabe RJ, Jeréz MB, Filippa VP, Gorlino CV, Autenrieth S, Autenrieth IB, Di Genaro MS. Yersinia enterocolitica YopH-deficient strain activates neutrophil recruitment to Peyer's patches promoting clearance of the virulent strain. Infect Immun 2016; 84(11):3172-81; PMID:27550935; http://dx.doi.org/10.1128/IAI.00568-16
   PubMed Web of Science ®Google Scholar
• Balada-Llasat J, Mecsas J. Yersinia has a tropism for B and T cell zones of lymph nodes that is independent of the type III secretion system. PLoS Pathog 2006; 2(9):e86; PMID:16948531; http://dx.doi.org/10.1371/journal.ppat.0020086
   PubMed Web of Science ®Google Scholar
• Bergman MA, Loomis WP, Mecsas J, Starnbach MN, Isberg RR. CD8(+) T cells restrict Yersinia pseudotuberculosis infection: Bypass of anti-phagocytosis by targeting antigen-presenting cells. PLoS Pathog 2009; 5(9):e1000573; PMID:19730693; http://dx.doi.org/10.1371/journal.ppat.1000573
   PubMed Web of Science ®Google Scholar
• Low JL, Chai CLL, Yao SQ. Bidentate inhibitors of protein tyrosine phosphatases. Antioxid Redox Signal 2013; 20(14):2225-50; http://dx.doi.org/10.1089/ars.2013.5710
   Web of Science ®Google Scholar
• Paudyal MP, Wu L, Zhang Z, Spilling CD, Wong CF. A new class of salicylic acid derivatives for inhibiting YopH of Yersinia pestis. Bioorg Med Chem 2014; 22(24):6781-8; PMID:25468042; http://dx.doi.org/10.1016/j.bmc.2014.10.042
   PubMed Web of Science ®Google Scholar
• Bottini A, Wu B, Barile E, De SK, Leone M, Pellecchia M. High-throughput screening (HTS) by NMR guided identification of novel agents targeting the protein docking domain of YopH. Chem Med Chem 2015; 11(8):919-27; http://dx.doi.org/10.1002/cmdc.201500441
   Web of Science ®Google Scholar
• Kuban-Jankowska A, Sahu K, Gorska M, Tuszynski J, Wozniak M. Chicoric acid binds to two sites and decreases the activity of the YopH bacterial virulence factor. Oncotarget 2016; 7(3):2229-38; PMID:26735581; http://dx.doi.org/10.18632/oncotarget.6812
   PubMed Web of Science ®Google Scholar
• Hansen A, Chaerkady R, Sharma J, Díaz-Mejía JJ, Tyagi N, Renuse S, Jacob HK, Pinto SM, Sahasrabuddhe NA, Kim M, et al. The Escherichia coli phosphotyrosine proteome relates to core pathways and virulence. PLoS Pathog 2013; 9(6):e1003403; PMID:23785281; http://dx.doi.org/10.1371/journal.ppat.1003403
   PubMed Web of Science ®Google Scholar
• Binder NB, Puchner A, Niederreiter B, Hayer S, Leiss H, Blüml S, Kreindl R, Smolen JS, Redlich K. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum 2013; 65(3):608-17; PMID:23280418; http://dx.doi.org/10.1002/art.37797
   PubMed Web of Science ®Google Scholar
• Sauvonnet N, Lambermont I, van der Bruggen P, Cornelis GR. YopH prevents monocyte chemoattractant protein 1 expression in macrophages and T-cell proliferation through inactivation of the phosphatidylinositol 3-kinase pathway. Mol Microbiol 2002; 45(3):805-15; PMID:12139625; http://dx.doi.org/10.1046/j.1365-2958.2002.03053.x
   PubMed Web of Science ®Google Scholar
• Malemud CJ. The PI3K/Akt/PTEN/mTOR pathway: A fruitful target for inducing cell death in rheumatoid arthritis? Future Med Chem 2015; 7(9):1137-47; PMID:26132523; http://dx.doi.org/10.4155/fmc.15.55
   PubMed Web of Science ®Google Scholar
• Nakamura I, Jimi E, Duong LT, Sasaki T, Takahashi N, Rodan GA, Suda T. Tyrosine phosphorylation of p130Cas is involved in actin organization in osteoclasts. J Biol Chem 1998; 273(18):11144-9; PMID:9556601; http://dx.doi.org/10.1074/jbc.273.18.11144
   PubMed Web of Science ®Google Scholar
• Goldring SR, Purdue PE, Crotti TN, Shen Z, Flannery MR, Binder NB, Ross FP, McHugh KP. Bone remodelling in inflammatory arthritis. Ann Rheum Dis 2013; 72(Suppl 2):ii52-5; PMID:23253928; http://dx.doi.org/10.1136/annrheumdis-2012-202199
   PubMed Web of Science ®Google Scholar
• Gerke C, Falkow S, Chien Y. The adaptor molecules LAT and SLP-76 are specifically targeted by Yersinia to inhibit T cell activation. J Exp Med 2005; 201(3):361-71; PMID:15699071; http://dx.doi.org/10.1084/jem.20041120
   PubMed Web of Science ®Google Scholar
• Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract 2012; 2012:283181; PMID:22567280; http://dx.doi.org/10.1155/2012/283181
   PubMedGoogle Scholar
• Zhao X, Guan J. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 2011; 63(8):610-5; PMID:21118706; http://dx.doi.org/10.1016/j.addr.2010.11.001
   PubMed Web of Science ®Google Scholar
• Tai Y, Chen L, Shen T. Emerging roles of focal adhesion kinase in cancer. Biomed Res Int 2015; 2015:690690; PMID:25918719; http://dx.doi.org/10.1155/2015/690690
   PubMed Web of Science ®Google Scholar
• Tanaka M, Shimamura S, Kuriyama S, Maeda D, Goto A, Aiba N. SKAP2 promotes podosome formation to facilitate tumor-associated macrophage infiltration and metastatic progression. Cancer Res 2015; 76(2):358-69; PMID:26577701; http://dx.doi.org/10.1158/0008-5472.CAN-15-1879
   PubMed Web of Science ®Google Scholar
• Barrett A, Pellet-Many C, Zachary IC, Evans IM, Frankel P. p130Cas: A key signalling node in health and disease. Cell Signal 2013; 25(4):766-77; PMID:23277200; http://dx.doi.org/10.1016/j.cellsig.2012.12.019
   PubMed Web of Science ®Google Scholar
• Yu P, Fu Y. Tumor-infiltrating T lymphocytes: Friends or foes? Lab Invest 2006; 86(3):231-45; PMID:16446705; http://dx.doi.org/10.1038/labinvest.3700389
   PubMed Web of Science ®Google Scholar
• Carr G, Berrue F, Klaiklay S, Pelletier I, Landry M, Kerr RG. Natural products with protein tyrosine phosphatase inhibitory activity. Methods 2013; 65(2):229; PMID:24056213; http://dx.doi.org/10.1016/j.ymeth.2013.09.007
   PubMed Web of Science ®Google Scholar
• Burrows TW. An antigen determining virulence in Pasteurella pestis. Nature 1956; 177(4505):426-7; PMID:13309325; http://dx.doi.org/10.1038/177426b0
   PubMed Web of Science ®Google Scholar
• Sawa T, Katoh H, Yasumoto H. V-antigen homologs in pathogenic gram-negative bacteria. Microbiol Immunol 2014; 58(5):267-85; PMID:24641673; http://dx.doi.org/10.1111/1348-0421.12147
   PubMed Web of Science ®Google Scholar
• Overheim KA, DePaolo RW, DeBord KL, Morrin EM, Anderson DM, Green NM, Brubaker RR, Jabri B, Schneewind O. LcrV plague vaccine with altered immunomodulatory properties. Infect Immun 2005; 73(8):5152-9; PMID:16041032; http://dx.doi.org/10.1128/IAI.73.8.5152-5159.2005
   PubMed Web of Science ®Google Scholar
• Quenee LE, Schneewind O. Plague vaccines and the molecular basis of immunity against Yersinia pestis. Hum Vaccin 2009; 5(12):817-23; PMID:19786842; http://dx.doi.org/10.4161/hv.9866
   PubMed Web of Science ®Google Scholar
• Ivanov MI, Hill J, Bliska JB. Direct neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrV. Clin Vaccine Immunol 2014; 21(5):667-73; PMID:24599533; http://dx.doi.org/10.1128/CVI.00013-14
   PubMed Web of Science ®Google Scholar
• Price SB, Cowan C, Perry RD, Straley SC. The Yersinia pestis V antigen is a regulatory protein necessary for Ca2(+)-dependent growth and maximal expression of low-Ca2+ response virulence genes. J Bacteriol 1991; 173(8):2649-57; PMID:1901573; http://dx.doi.org/10.1128/jb.173.8.2649-2657.1991
   PubMed Web of Science ®Google Scholar
• Pettersson J, Holmström A, Hill J, Leary S, Frithz-Lindsten E, von Euler-Matell A, Carlsson E, Titball R, Forsberg A, Wolf-Watz H. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 1999; 32(5):961-76; PMID:10361299; http://dx.doi.org/10.1046/j.1365-2958.1999.01408.x
   PubMed Web of Science ®Google Scholar
• Mota LJ. Type III secretion gets an LcrV tip. Trends Microbiol 2006; 14(5):197-200; PMID:16564172; http://dx.doi.org/10.1016/j.tim.2006.02.010
   PubMed Web of Science ®Google Scholar
• Holmstrom A, Olsson J, Cherepanov P, Maier E, Nordfelth R, Pettersson J, Benz R, Wolf-Watz H, Forsberg A. LcrV is a channel size-determining component of the Yop effector translocon of Yersinia. Mol Microbiol 2001; 39(3):620-32; PMID:11169103; http://dx.doi.org/10.1046/j.1365-2958.2001.02259.x
   PubMed Web of Science ®Google Scholar
• Broz P, Mueller CA, Müller SA, Philippsen A, Sorg I, Engel A, Cornelis GR. Function and molecular architecture of the Yersinia injectisome tip complex. Mol Microbiol 2007; 65(5):1311-20; PMID:17697254; http://dx.doi.org/10.1111/j.1365-2958.2007.05871.x
   PubMed Web of Science ®Google Scholar
• Ekestubbe S, Broms JE, Edgren T, Fallman M, Francis MS, Forsberg A. The amino-terminal part of the needle-tip translocator LcrV of Yersinia pseudotuberculosis is required for early targeting of YopH and in vivo virulence. Front Cell Inf Microbiol 2016; 6:175; PMID:2799509; http://dx.doi.org/10.3389/fcimb.2016.00175
   PubMed Web of Science ®Google Scholar
• Fields KA, Straley SC. LcrV of Yersinia pestis enters infected eukaryotic cells by a virulence plasmid-independent mechanism. Infect Immun 1999; 67(9):4801-13; PMID:10456934
   PubMed Web of Science ®Google Scholar
• Motin VL, Nakajima R, Smirnov GB, Brubaker RR. Passive immunity to Yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 1994; 62(10):4192-4201; PMID:7927675
   PubMed Web of Science ®Google Scholar
• Nedialkov YA, Motin VL, Brubaker RR. Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: Amplification of interleukin-10. Infect Immun 1997; 65(4):1196-1203; PMID:9119451
   PubMed Web of Science ®Google Scholar
• Sing A, Roggenkamp A, Geiger AM, Heesemann J. Yersinia enterocolitica evasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice. J Immunol 2002; 168(3):1315-21; PMID:11801671; http://dx.doi.org/10.4049/jimmunol.168.3.1315
   PubMed Web of Science ®Google Scholar
• Welkos S, Friedlander A, McDowell D, Weeks J, Tobery S. V antigen of Yersinia pestis inhibits neutrophil chemotaxis. Microb Pathog 1998; 24(3):185-96; PMID:9514641; http://dx.doi.org/10.1006/mpat.1997.0188
   PubMed Web of Science ®Google Scholar
• Sodhi A, Sharma RK, Batra HV. Yersinia rLcrV and rYopB inhibits the activation of murine peritoneal macrophages in vitro. Immunol Lett 2005; 99(2):146-52; PMID:16009264; http://dx.doi.org/10.1016/j.imlet.2005.02.009
   PubMed Web of Science ®Google Scholar
• Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J. Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 2002; 196(8):1017-24; PMID:12391013; http://dx.doi.org/10.1084/jem.20020908
   PubMed Web of Science ®Google Scholar
• Brubaker RR. Interleukin-10 and inhibition of innate immunity to Yersiniae: Roles of Yops and LcrV (V antigen). Infect Immun 2003; 71(7):3673-81; PMID:12819047; http://dx.doi.org/10.1128/IAI.71.7.3673-3681.2003
   PubMed Web of Science ®Google Scholar
• Roggenkamp A, Geiger AM, Leitritz L, Kessler A, Heesemann J. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 1997; 65(2):446-51; PMID:9009295
   PubMed Web of Science ®Google Scholar
• Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10(3):170-81; PMID:20154735; http://dx.doi.org/10.1038/nri2711
   PubMed Web of Science ®Google Scholar
• Fioranelli M, Grazia RM. Twenty-five years of studies and trials for the therapeutic application of IL-10 immunomodulating properties. From high doses administration to low dose medicine new paradigm. J Integr Cardiol 2015; 1(1):2-6
   Google Scholar
• O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008; 223:114-31; PMID:18613832; http://dx.doi.org/10.1111/j.1600-065X.2008.00635.x
   PubMed Web of Science ®Google Scholar
• Tian G, Li J, Wang D, Zhou D. Targeting IL-10 in auto-immune diseases. Cell Biochem Biophys 2014; 70(1):37-49; PMID:24639111; http://dx.doi.org/10.1007/s12013-014-9903-x
   PubMed Web of Science ®Google Scholar
• Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y, Li N, Wei F. Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells. F1000Res 2015; 4(F1000 Faculty Rev): 1465; http://dx.doi.org/10.12688/f1000research.6003.2
   PubMedGoogle Scholar
• Wei P, Wong WW, Park JS, Corcoran EE, Peisajovich SG, Onuffer JJ, Weiss A, Lim WA. Bacterial virulence proteins as tools to rewire kinase pathways in yeast and immune cells. Nature 2012; 488(7411):384-8; PMID:22820255; http://dx.doi.org/10.1038/nature11259
   PubMed Web of Science ®Google Scholar
• Uusna J, Langel K, Langel Ü. Toxicity, immunogenicity, uptake, and kinetics methods for CPPs. Methods Mol Biol 2015; 1324:133-48; PMID:26202267; http://dx.doi.org/10.1007/978-1-4939-2806-4_9
   PubMedGoogle Scholar
• Kim HY, Yum SY, Jang G, Ahn D. Discovery of a non-cationic cell penetrating peptide derived from membrane-interacting human proteins and its potential as a protein delivery carrier. Sci Rep 2015; 5:11719; PMID:26114640; http://dx.doi.org/10.1038/srep11719
   PubMed Web of Science ®Google Scholar
• Pan R, Xu W, Jafari M, Chen B, Sheinin T, Chen P. DEGylation enhanced the stability of peptide-siRNA complexes in serum. J Nanosci Nanotechnol 2015; 15(12):9982-90; PMID:26682443; http://dx.doi.org/10.1166/jnn.2015.12074
   PubMed Web of Science ®Google Scholar
• Ruckdeschel K, Machold J, Roggenkamp A, Schubert S, Pierre J, Zumbihl R, Liautard JP, Heesemann J, Rouot B. Yersinia enterocolitica promotes deactivation of macrophage mitogen-activated protein kinases extracellular signal-regulated kinase-1/2, p38, and c-Jun NH2-terminal kinase. Correlation with its inhibitory effect on tumor necrosis factor-alpha production. J Biol Chem 1997; 272(25):15920-7; PMID:9188492; http://dx.doi.org/10.1074/jbc.272.25.15920
   PubMed Web of Science ®Google Scholar
• Green SP, Hartland EL, Robins-Browne RM, Phillips WA. Role of YopH in the suppression of tyrosine phosphorylation and respiratory burst activity in murine macrophages infected with Yersinia enterocolitica. J Leukoc Biol 1995; 57(6):972-7; PMID:7790780
   PubMed Web of Science ®Google Scholar
• Ruckdeschel K, Roggenkamp A, Schubert S, Heesemann J. Differential contribution of Yersinia enterocolitica virulence factors to evasion of microbicidal action of neutrophils. Infect Immun 1996; 64(3):724-33; PMID:8641773
   PubMed Web of Science ®Google Scholar
• Visser LG, Seijmonsbergen E, Nibbering PH, van den Broek P J, van Furth R. Yops of Yersinia enterocolitica inhibit receptor-dependent superoxide anion production by human granulocytes. Infect Immun 1999; 67(3):1245-50; PMID:10024567
   PubMed Web of Science ®Google Scholar
• Viboud GI, So SSK, Ryndak MB, Bliska JB. Proinflammatory signalling stimulated by the type III translocation factor YopB is counteracted by multiple effectors in epithelial cells infected with Yersinia pseudotuberculosis. Mol Microbiol 2003; 47(5):1305-15; PMID:12603736; http://dx.doi.org/10.1046/j.1365-2958.2003.03350.x
   PubMed Web of Science ®Google Scholar
• Black DS, Bliska JB. Identification of p130Cas as a substrate of Yersinia YopH (Yop51), a bacterial protein tyrosine phosphatase that translocates into mammalian cells and targets focal adhesions. EMBO J 1997; 16(10):2730-44; PMID:9184219; http://dx.doi.org/10.1093/emboj/16.10.2730
   PubMed Web of Science ®Google Scholar
• Persson C, Carballeira N, Wolf-Watz H, Fällman M. The PTPase YopH inhibits uptake of Yersinia, tyrosine phosphorylation of p130Cas and FAK, and the associated accumulation of these proteins in peripheral focal adhesions. EMBO J 1997; 16(9):2307-18; PMID:9171345; http://dx.doi.org/10.1093/emboj/16.9.2307
   PubMed Web of Science ®Google Scholar
• Black DS, Montagna LG, Zitsmann S, Bliska JB. Identification of an amino-terminal substrate-binding domain in the Yersinia tyrosine phosphatase that is required for efficient recognition of focal adhesion targets. Mol Microbiol 1998; 29(5):1263-74; PMID:9767593; http://dx.doi.org/10.1046/j.1365-2958.1998.01014.x
   PubMed Web of Science ®Google Scholar
• Mecsas J, Raupach B, Falkow S. The Yersinia Yops inhibit invasion of Listeria, Shigella and Edwardsiella but not Salmonella into epithelial cells. Mol Microbiol 1998; 28(6):1269-81; PMID:9680215; http://dx.doi.org/10.1046/j.1365-2958.1998.00891.x
   PubMed Web of Science ®Google Scholar
• Deleuil F, Mogemark L, Francis MS, Wolf-Watz H, Fällman M. Interaction between the Yersinia protein tyrosine phosphatase YopH and eukaryotic Cas/Fyb is an important virulence mechanism. Cell Microbiol 2003; 5(1):53-64; PMID:12542470; http://dx.doi.org/10.1046/j.1462-5822.2003.00236.x
   PubMed Web of Science ®Google Scholar
• Hamid N, Gustavsson A, Andersson K, McGee K, Persson C, Rudd CE, Fällman M. YopH dephosphorylates Cas and Fyn-binding protein in macrophages. Microb Pathog 1999; 27(4):231-42; PMID:10502464; http://dx.doi.org/10.1006/mpat.1999.0301
   PubMed Web of Science ®Google Scholar
• Black DS, Marie-Cardine A, Schraven B, Bliska JB. The Yersinia tyrosine phosphatase YopH targets a novel adhesion-regulated signalling complex in macrophages. Cell Microbiol 2000; 2(5):401-14; PMID:11207596; http://dx.doi.org/10.1046/j.1462-5822.2000.00061.x
   PubMed Web of Science ®Google Scholar
• Yuan M, Deleuil F, Fällman M. Interaction between the Yersinia tyrosine phosphatase YopH and its macrophage substrate, Fyn-binding protein, Fyb. J Mol Microbiol Biotechnol 2005; 9(3–4):214-23; PMID:16415594; http://dx.doi.org/10.1159/000089649
   PubMed Web of Science ®Google Scholar
• Bliska JB, Black DS. Inhibition of the Fc receptor-mediated oxidative burst in macrophages by the Yersinia pseudotuberculosis tyrosine phosphatase. Infect Immun 1995; 63(2):681-5; PMID:7822039
   PubMed Web of Science ®Google Scholar
• Fällman M, Andersson K, Hakansson S, Magnusson KE, Stendahl O, Wolf-Watz H. Yersinia pseudotuberculosis inhibits Fc receptor-mediated phagocytosis in J774 cells. Infect Immun 1995; 63(8):3117-24; PMID:7622239
   PubMed Web of Science ®Google Scholar
• Yao T, Mecsas J, Healy JI, Falkow S, Chien Y. Suppression of T and B lymphocyte activation by a Yersinia pseudotuberculosis virulence factor, yopH. J Exp Med 1999; 190(9):1343-50; PMID:10544205; http://dx.doi.org/10.1084/jem.190.9.1343
   PubMed Web of Science ®Google Scholar
• Rolán HG, Durand EA, Mecsas J. Identifying Yersinia YopH-targeted signal transduction pathways that impair neutrophil responses during in vivo murine infection. Cell Host Microbe 2013; 14(3):306-17; PMID:24034616; http://dx.doi.org/10.1016/j.chom.2013.08.013
   PubMed Web of Science ®Google Scholar
• La Puerta ML, de, Trinidad AG, del Carmen Rodríguez M, Bogetz J, Sánchez Crespo M, Mustelin T, Alonso A, Bayón Y. Characterization of new substrates targeted by Yersinia tyrosine phosphatase YopH. PLoS One 2009; 4(2):e4431; PMID:19221593; http://dx.doi.org/10.1371/journal.pone.0004431
   PubMed Web of Science ®Google Scholar
• Choi HW, Brooking-Dixon R, Neupane S, Lee C, Miao EA, Staats HF, Abraham SN. Salmonella typhimurium impedes innate immunity with a mast-cell-suppressing protein tyrosine phosphatase, SptP. Immunity 2013; 39(6):1108-20; PMID:24332031; http://dx.doi.org/10.1016/j.immuni.2013.11.009
   PubMed Web of Science ®Google Scholar